MedTrace Logo

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

NCT03286530 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-03-27

No results posted yet for this study

Summary

This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is:

• Ruxolitinib

Conditions

Interventions

DRUG

Ruxolitinib

Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib. After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment.

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Vanderbilt University

    collaborator OTHER

  • Ohio State University

    collaborator OTHER

  • Medical College of Wisconsin

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Gabriell Hobbs, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-03
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03286530 on ClinicalTrials.gov